Document is current
Any future updates will be listed below
-
Authors
Wen, Chengxi
Liu, Yifeng
Li, Yanzhi
Chen, Ruiying
Zhao, Hao
Zhang, Xiaojuan
Zhuang, Xiaoxin
Liao, Yuhua
Hao, Jiejing
Chen, Yan
Wang, Wanxin
Zhang, Huiming
Guo, Lan
McIntyre, Roger S.
Teopiz, Kayla M.
Lu, Ciyong
Han, Xue
-
Funding
Funding for this research was provided by:
the National Natural Science Foundation of China (82373660)
Sanming Project of Medicine in Shenzhen Nanshan (11)
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 7 May 2025
First Online: 14 May 2025
Declarations
:
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration. All procedures involving human patients were approved by the Institutional Review Board of Sun Yat-sen University School of Public Health (Ethical code: L2017044). All participants signed informed consent after detailed understanding of the study protocol.
: Not applicable.
: Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Kayla M. Teopiz has received fees from Braxia Scientific Corp. Other authors declare that they have no competing interests.
